All scientific sessions take place in the Clyde Auditorium unless otherwise noted.
SUNDAY 9 NOVEMBER
SS1
11.00–12.30
Satellite Symposium: Pfizer
HAART: Escaping the ‘Red-Queen Effect’. Will new
treatments enable us to win the evolution challenge?
SS1CH
Chairs: Santiago Moreno (Spain)
Mark Nelson (UK)
SS1.1
“Begin at the beginning and go on until you come to
the end. Read the directions and directly you will be
directed in the right direction”
The role of CCR5 antagonists in ART-strategy; when
and how to use them
Jürgen Rockstroh (Germany)
SS1.2
“Curioser and curioser”
Nucleoside sparing regimens: why do we need them?
Graeme Moyle (UK)
SS1.3
“I think I should understand that better . . .”
How important is CD4 count and how to increase it?
Yves Levy (France)
Panel discussion
12.30–13.30
LUNCH
SS2
13.30–15.00
Satellite Symposium: Merck Sharp & Dohme
Reaching new heights in HIV management
SS2CH
Chair: Brian Gazzard (UK)
SS2CH
13.30–13.35
Opening remarks
Brian Gazzard (UK)
SS2.1
13.35–13.55
HIV Treatment Goals: updated guidelines and new
therapeutic opportunities
Brian Gazzard (UK)
SS2.2
13.55–14.20
The evolving role of raltegravir in HIV management
Calvin Cohen (USA)
SS2.3
14.20–14.45
New possibilities in HIV management: real-world
experience
Christine Katlama (France)
14.45–14.55
Panel discussion
SS2CH
14.55–15.00
Closing remarks
Brian Gazzard (UK)
15.00–15.30
COFFEE
SS3
15.30–17.00
Satellite Symposium: GlaxoSmithKline PLC
Pieces of the puzzle – unlocking the potential of
personalised medicine
SS3CH
Chair: Peter Reiss (The Netherlands)
SS3CH
15.30–15.40
Introduction
Peter Reiss (The Netherlands)
SS3.1
15.40–16.00
Translating evidence into practice – efficacy of NRTIs
SS3.2
16.00–16.20
Personalisation – patients and choices –
understanding safety and long-term treatments
Esteban Martínez (Spain)
16.20–16.30
Questions and answers for Professor Perno and
Professor Martínez
SS3.3
16.30–16.50
A new way of thinking – sharing experiences from
cardiovascular risk in rheumatoid arthritis
George Kitas (UK)
16.50–16.55
Questions and answers for Professor Kitas
SS3CH
16.55–17.00
Closing remarks
Peter Reiss (The Netherlands)
17.00–17.30
COFFEE
17.30–18.00
Official Opening
Ed Byrne, Executive Dean of Biomedicine, Head of
University College London Medical School (UCLMS)
and Vice Provost (Health) (UK)
Brian Williams, President, Royal College of Physicians
and Surgeons of Glasgow (UK)
KL
18.00–19.30
Keynote Lectures
KL1
18.00–18.30
Pathogenesis of HIV infection: implications for
treatment and prevention
Clifford Lane (USA)
KL2
18.30–19.00
How will we use the new ART drugs?
Christine Katlama (France)
KL3
19.00–19.30
The implications beyond public health if we don’t
manage the HIV epidemic
Alan Whiteside (South Africa)
19.30–20.30
WELCOME RECEPTION
MONDAY 10 NOVEMBER
O11
08.30–10.25
Antiretroviral Resistance: What You Want to Know
O11CH
Chairs: Jonathan Schapiro (Israel)
Anders Sönnerborg (Sweden)
O111
08.30–08.50
Global impact of HIV drug resistance
Deenan Pillay (UK)
O112
08.50–09.05
Trends in transmitted HIV drug resistance among
non-B subtypes in the UK
Daniella Chilton (UK)
O113
09.05–09.20
HIV-1 clade C resistance genotypes after first
virological failure in a large community ART
programme
Catherine Orrell (South Africa)
O114
09.20–09.35
NNRTI mutations are efficiently transmitted within
clusters of new HIV infections
SCIENTIFIC PROGRAMME (continued)
O115
09.35–09.55
Importance of detecting minority variants in the
clinical management of HIV
Dan Kuritzkes (USA)
09.55–10.25
Panel discussion and questions
10.25–10.55
COFFEE
O12
10.55–12.40
Essential Pharmacology
O12CH
Chairs: David Back (UK)
Janet Darbyshire (UK)
O121
10.55–11.10
Prevalence of drug interactions between
antiretroviral and co-administered drugs at the MOI
teaching and referral hospital (Ampath), Eldoret,
Kenya
Saye Khoo (UK)
O122
11.10–11.25
To overdose or underdose? The question of Kaletra
in children in the UK/Irish Collaborative HIV
Paediatric Study (CHIPS)
Sarah Walker (UK)
O123
11.25–11.45
Drug interactions that really matter
Saye Khoo (UK)
O124
11.45–12.00
Efavirenz and rifampicin in the South African context:
is there a need to dose increase efavirenz with
concurrent rifampicin therapy?
Catherine Orrell (South Africa)
O125
12.00–12.15
Impact of efavirenz and nevirapine on
pharmacokinetics of lopinavir/ritonavir as tablets and
capsules in African patients
Cissy Kityo (Uganda)
12.15–12.40
Panel discussion
12.40–14.10
LUNCH AND POSTERS
(including Poster Discussion Sessions)
Hall 4, Room 1
13.00–14.00
Treatment Strategies: Naïve Patients
PCH
Chairs: Brian Gazzard (UK)
Alain Volny-Anne (France)
P1
Clinical effect of interleukin-2 (IL-2) immuno-adjuvant
treatment in HIV+ advanced naïve patients
Camilla Tincati (Italy)
P2
Efficacy and safety of TMC278 in treatment-naïve,
HIV-infected patients: week 96 data from
TMC278-C204
Katia Boven (USA)
P3
Impact of antiretroviral dosing and daily pill burden
on viral rebound rates in naïve patients receiving a
tenofovir-based regimen
Andrea Antinori (Italy)
P53
Efficacy and safety of switching from lopinavir/r to
atazanavir/r in suppressed patients receiving a
LPV/r-containing HAART: ATAZIP 96-week results
P54
48-week outcomes following switch from AZT/3TC
to FTC/TDF (TVD) vs. continuing on AZT/3TC:
48-week interim analysis of the RECOMB trial
Esteban Ribera (Spain)
P306
NRTI backbone pairs for treatment-naïve adults with
HIV infection: a UK economic evaluation
Edward Hutt (USA)
Hall 4, Room 2
13.00–14.00
Strategies for the Experienced: Immunology and
Inflammation, the Lung, and Sex
PCH
Chairs: Judith Currier (USA)
Simone Marcotullio (Italy)
P61
Simplification of therapy (ART) with efavirenz/
emtricitabine/tenofovir DF single tablet regimen vs.
continued ART in suppressed, HIV-infected patients
Ben Young (USA)
P167
Effect of a fixed-dose combination of emtricitabine,
tenofovir and efavirenz on adherence and treatment
acceptability (ADONE study)
Franco Maggiolo (Italy)
P70
Evolution of CD4+ T-cell count in HIV-1 infected
adults receiving antiretroviral therapy with sustained
long-term virological suppression
Helen Byakwaga (Australia)
P297
Changes in CCR5+ cells and antigen-specific
CD4+ T-cells during monotherapy with a CCR5
antagonist SCH532706 compared with combination
therapy
Sarah Pett (Australia)
P213
D-dimer and anti-coagulation activity markers in
children and adolescents with HIV infection
Giuseppe Pontrelli (Italy)
P299
What about primary pulmonary hypertension in HIV
infection in the era of combination antiretroviral
therapy?
Murielle Mary-Krause (France)
P71
Virological treatment outcome under HAART: does
sex matter?
Annette Haberl (Denmark)
14.10–14.20
The HIV Research Trust: Report on Progress
Robert Souhami, Chairperson of the HIV Research
Trust (UK)
O13
14.20–16.30
Headlines from Resource-poor Settings
IAS Session
O13CH
Chairs: Pedro Cahn (Argentina)
Ade Fakoya (International AIDS Alliance, and UK)
O131
14.20–14.40
Where are we with National and International
guidelines?
Elly Katabira (Uganda)
O133
15.00–15.20
HIV/TB: when is it safe to start HAART?
Robin Wood (South Africa)
O134
15.20–15.40
HIV disease management and challenges in Eastern
Europe and Central Asia
Alexey Bobrik (Russian Federation)
O135
15.40–16.00
Seek and treat for optimal prevention of HIV/AIDS
(STOP HIV/AIDS)
Julio Montaner (Canada)
16.00–16.30
Panel discussion
16.30–17.00
COFFEE
SS4
17.00–18.30
Satellite Symposium: Boehringer Ingelheim GmbH
Aiming for the long-term: focus on the individual
SS4CH
Chair: José Gatell (Spain)
SS4CH
17.00–17.05
Welcome and introduction
José Gatell (Spain)
SS4.1
17.05–17.25
Considering the individual – principles of treatment
choice
Laura Waters (UK)
SS4.2
17.25–17.50
Initiating and maintaining HAART – aiming for the
long term in treatment-naïve patients
Georg Behrens (Germany)
SS4.3
17.50–18.20
Understanding PI resistance – aiming for the long
term in treatment-experienced patients
Anna Maria Geretti (UK)
18.20–18.30
Panel discussion
TUESDAY 11 NOVEMBER
O21
08.30–09.50
The CNS, Immune Response and Treatment
Interruption Revisited
O21CH
Chairs: Margaret Johnson (UK)
Stefano Vella (Italy)
O211
08.30–08.50
HIV and the brain: neuro-inflammation long-term,
CNS control of HIV replication, brain disease in
suppressed patients and differential penetration
of drugs
David Clifford (USA)
O212
08.50–09.05
Rate of change in CD4 counts in patients with stable
HIV viraemia
Amanda Mocroft (UK)
O213
09.05–09.20
CD4–guided STI in patients responding to HAART
Franco Maggiolo (Italy)
O214
09.20–09.35
The FOTO study: 24-week results support the safety
of a 2-day break on efavirenz-based antiretroviral
therapy
Calvin Cohen (USA)
09.35–09.50
Panel discussion
09.50–10.20
COFFEE
O22
10.20–12.15
Children: From Birth to Longevity
O22CH
Chairs: Hermione Lyall (UK)
Ian Weller (UK)
O221
10.20–10.35
Antiretroviral Pregnancy Registry (APR) at 10,000
prospective reports
Karen Beckerman (USA)
O222
10.35–10.50
Treatment interruption in children with chronic
HIV-infection: the results of the paediatric European
network for treatment of AIDS (PENTA) 11 trial
Di Gibb (UK)
O223
10.50–11.10
Optimising paediatric treatment for long-term
survival. Adult survivors of congenital HIV infection:
what problems will they have?
Hermione Lyall (UK)
11.10–11.25
Panel discussion
O224
11.25 –12.15
Special Guest Lecture
The early AIDS Epidemic in the US: views from
Atlanta and Hollywood
Harold Jaffe (UK)
12.15–13.45
LUNCH AND POSTERS
(including Poster Discussion Sessions)
CoS
12.25–13.45
Community Session
Lomond Auditorium
Can HAART Prevent HIV Transmission?
CoSCH
Chairs: Sean Hosein (Canada)
Alain Volny-Anne (France)
Earlier this year the Swiss Federal AIDS Commission
published a paper stating that having an undetectable
viral load made HIV positive people non-infectious.
This position paper has incited intense controversy,
being published against a background of increasing
criminalisation of HIV transmission, difficulty of
disclosure, and the psychological burden of living with
a stigmatised and chronic illness.
The internationally renowned panel members will each
make a 10-minute presentation on their perspective that
will serve as a foundation for the insightful and spirited
discussion that will follow.
CoS.1
Bernard Hirschel (Switzerland)
CoS.2
Cate Hankins (Switzerland)
CoS.3
Paul MacPherson (Canada)
SCIENTIFIC PROGRAMME (continued)
Hall 4, Room 1
12.30–13.30
Adverse Events
PCH
Chairs: Simon Mallal (Australia)
Fiona Mulcahy (Ireland)
P128
Kidney tubular abnormalities in HIV patients treated
with tenofovir with normal glomerular function:
results of a prospective study on 284 patients
Pablo Labarga (Spain)
P150
Frequency of bone abnormalities and associated
factors in a Spanish cohort of HIV-infected patients
Anna Bonjoch (Spain)
P234
Improvement of atazanavir-induced
hyperbilirubinaemia following TDM-guided atazanavir
dose reduction
Massimo Giola (Italy)
P288
Predictors of immune reconstitution inflammatory
syndrome associated with Kaposi sarcoma (IRIS-KS)
in a rural area of Mozambique
Emilio Letang (Spain)
P289
Impact of HIV treatment on clearance of human
papillomavirus (HPV) infection in HIV-infected
women
Deborah Konopnicki (Belgium)
Hall 4, Room 2
12.30–13.30
Treatment Strategies: Experienced Patients
PCH
Chairs: Andrzej Horban (Poland)
Andrew Phillips (UK)
P20
Raltegravir: a potent and safe integrase inhibitor
with a favourable impact on cardiovascular and
liver profile
Francisco Blanco (Spain)
P21
POWER 1 and 2: combined final 144-week efficacy
and safety results for darunavir/ritonavir (DRV/r)
600/100 mg BID in treatment-experienced HIV
patients
Christine Katlama (France)
P22
Phase III TITAN week 96 final analysis: efficacy/
safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r)
in LPV-naïve, treatment-experienced patients
Christine Katlama (France)
P23
Virological response with fully active etravirine (ETR;
TMC125) after 48 weeks of treatment: pooled results
from the DUET-1 and DUET-2 trials
Nathan Clumeck (Belgium)
O23
13.45–15.00
Hepatic Headlines
O23CH
Chairs: Antonella d’Arminio Monforte (Italy)
Stephen Storfer (USA)
O231
13.45–14.00
Cryptogenic liver disease, steatosis, portal
hypertension, transaminitis and antiretrovirals
O232
14.00–14.15
What’s new in hepatitis C?
Vincent Soriano (Spain)
O233
14.15–14.30
Surrogate markers for liver damage: how can we
measure the extent of fibrosis and disease without
biopsy?
Massimo Puoti (Italy)
14.30–15.00
Panel discussion
CS1
15.00–16.30
Assessment of the Sick HIV-positive Returning
Traveller: Case Studies Session held in collaboration
with European AIDS Clinical Society
CS1CH
Chairs: Manuel Battegay (Switzerland)
Peter Reiss (The Netherlands)
Panel: Nathan Clumeck (Belgium)
Bob Colebunders (Belgium)
John Gill (Canada)
Alison Grant (UK)
Roy Gulick (USA)
Christoph Hatz (Switzerland)
15.20–16.10
Cases
CS1.1
•
Traveller going to tropical region
Aisling Loy (Ireland)
CS1.2
•
Immigrant arriving from sub-Saharan Africa
Michele van Vugt (The Netherlands)
CS1.3
•
Traveller returning with diarrhoea
Emilio Letang (Spain)
CS1.4
•
Traveller returning with fever
Yves van Laethem (Belgium)
CS1.5
16.10–16.30
Mini-review: Important issues considering sick
HIV-positive returning traveller or immigrant from
a tropical region
Christoph Hatz (Switzerland)
16.30–17.00
COFFEE
SS5
17.00–18.30
Satellite Symposium: Bristol-Myers Squibb
The burden of choice
SS5CH
Chair: Jürgen Rockstroh (Germany)
SS5CH
17.00–17.10
Introduction
Jürgen Rockstroh (Germany)
SS5.1
17.10–17.35
Why NNRTIs should be the standard in treatment
initiation
Mark Nelson (UK)
SS5.2
17.35–18.00
Why PIs should be the standard in treatment
initiation
Calvin Cohen (USA)
18.00–18.20
Interactive discussion session
Calvin Cohen, Mark Nelson and Jürgen Rockstroh
SS5.3
18.20–18.30
Is choice still a burden? Keep it simple!
Jürgen Rockstroh (Germany)
SCIENTIFIC PROGRAMME (continued)
ES1
18.30–20.00
Evening Symposium: Abbott
Lomond
Clinical dialogues: Face-to-face with today’s practice
Auditorium
challenges
ES1CH
Chair: Ed Wilkins (UK)
ES1CH
18.30–18.35
Welcome
Ed Wilkins (UK)
ES1.1
18.35–18.55
Flexible treatment regimens: A prelude to improved
outcomes?
François Raffi (France)
ES1.2
18.55–19.15
Case study dialogue: Addressing the complexities of
long-term ARV treatment
François Raffi (France)
Panel discussion
Moderated by Ed Wilkins (UK), joined by
Bruno Spire (France), François Raffi (France) and
Pere Domingo (Spain)
ES1.3
19.15–19.35
Lipoatrophy: Untangling the differences among ARVs
Pere Domingo (Spain)
ES1.4
19.35–19.55
Case study dialogue: Reflecting on lipoatrophy and
body fat changes
Ed Wilkins (UK)
Panel discussion
Moderated by Ed Wilkins (UK), joined by
Bruno Spire (France), François Raffi (France) and
Pere Domingo (Spain)
ES1CH
19.55–20.00
Summary and close
Ed Wilkins (UK)
ES2
18.30–20.00
Evening Symposium: Tibotec, a division of
Hall 2
Janssen-Cilag Ltd
Spanning the treatment spectrum for HIV-1-infected
patients: A new era?
ES2CH
Chair: Anton Pozniak (UK)
ES2CH
18.30–18.35
Welcome and introduction
Anton Pozniak (UK)
ES2.1
18.35–18.50
A new era in the management of HIV-infected
patients
Bernard Hirschel (Switzerland)
ES2.2
18.50–19.10
Optimising treatment outcomes for
treatment-experienced patients
Giovanni Di Perri (Italy)
ES2.3
19.10–19.30
Providing treatment-naïve HIV-1-infected patients
with optimal care
Hans-Jürgen Stellbrink (Germany)
ES2.4
19.30–19.45
Looking to the future: expanding opportunities
across the treatment spectrum
Christine Katlama (France)
19.45–20.00
Panel discussion
ES2CH
20.00
Closing remarks
WEDNESDAY 12 NOVEMBER
O31
08.30–10.10
‘Non-AIDS Morbidities’: Part of Life, HIV Disease
and/or Adverse Events of Therapy
O31CH
Chairs: David Cooper (Australia)
Ray Fox (UK)
O311
08.30–08.50
Pathogenesis of non-AIDS morbidities in HIV disease
and implications for management
Steven Deeks (USA)
O312
08.50–09.10
Cardiovascular disease; HIV, ART, immunodeficiency,
pro-inflammation and other factors
Jens Lundgren (Denmark)
O313
09.10–09.25
Relation between adverse effects of ARV treatment
and underlying risk in number needed to treat
to harm (NNTH): myocardial infarction and
abacavir use
Justyna Kowalska (Denmark)
O314
09.25-09.40
Predicting the short-term risk of diabetes in
HIV-infected patients in the D:A:D cohort: the D:A:D
study group
Kathy Petoumenos (Australia)
09.40–10.10
Panel discussion
10.10–10.40
COFFEE
O32
10.40–12.15
Cancer, Bone and Renal Disease
O32CH
Chairs: William Powderly (Ireland)
Rainer Weber (Switzerland)
O321
10.40–11.00
HIV, immune deficiency and malignancy
Andrew Grulich (Australia)
O322
11.00–11.20
Bone disease and HIV: together for the long term
Patrick Mallon (Ireland)
O323
11.20–11.35
High HIV viral load inhibits osteoblast function and
signalling
Nicholas Chew (Ireland)
O324
11.35–11.55
Management of renal disease in HIV infection for the
HIV physician
Ian Williams (UK)
11.55–12.15
Panel discussion
12.15–13.45
LUNCH AND POSTERS
(including Poster Discussion Sessions)
Hall 4, Room 1
12.30–13.30
HIV-related Infections, Co-infections and Cancers:
Hepatitis Co-infection (HCV and HBV)
PCH
Chairs: NM Samuel (India)
Mauro Schechter (Brazil)
P134
Risk factors for end-stage liver disease among HIV
and hepatitis C virus co-infected patients in the
Spanish VACH Cohort
SCIENTIFIC PROGRAMME (continued)
P135
Screening for liver fibrosis in HIV-mono-infected
patients with increased ALT comparing FibroScan
with FIB-4
Stefan Mauss (Denmark)
P264
Cross-sectional study to determine prevalence of
significant liver fibrosis (F2-F4) in HIV/HCV
co-infected patients: GRAFIHCO study
Angel Burgos (Spain)
P265
A 4-year follow-up of a cohort of HIV-positive
cirrhotic patients
Paula Tuma (Spain)
P266
Rapid virological response is the best predictor for
achieving SVR under peg-IFN/ribavirin hepatitis C
therapy in HIV/HCV co-infected patients
Jürgen Rockstroh (Germany)
P267
Switching from zidovudine/lamivudine (ZDV/LMV) to
tenofovir/emtricitabine (TDF/FTC) or abacavir/
lamivudine (ABC/LMV) in HIV/HCV co-infection
(COTKI study)
Paola Nasta (Italy)
P268
HCV relapse after peg-interferon (IFN) plus ribavirin
(RBV) therapy: is 12-week follow-up enough to
determine sustained HCV clearance?
Jose Medrano (Spain)
Hall 4, Room 1
12.30–13.30
Laboratory Monitoring of Disease and Therapy
PCH
Chairs: Saye Khoo (UK)
Veronica Miller (USA)
P178
Re-evaluation of resistance algorithms for
lopinavir/ritonavir in the TITAN trial
Vincent Calvez (France)
P197
Validation of an enhanced sensitivity Trofile™ HIV-1
co-receptor tropism assay for selecting patients for
therapy with entry inhibitors targeting CCR5
Jacqueline Reeves (USA)
P198
Prevalence of CCR5-tropic HIV-1 among
treatment-experienced individuals in South Africa infected with
Clade C virus
Sybil Eng (USA)
P199
Therapeutic drug monitoring of new formulation
Kaletra in pregnancy
Laura Else (UK)
P241
Modelling the change in lopinavir apparent oral
clearance over time following cessation of
lopinavir/ritonavir: data from the TAIL study
O33
13.45–15.00
Important Recent Findings from Cohort Studies
O33CH
Chairs: Cristina Mussini (Italy)
Jeff Nadler (USA)
O331
13.45–14.00
Patterns of viral suppression on cART as predictors
of uncontrolled viraemia after starting a new
antiretroviral after 1 January 2003
Joanne Reekie (UK)
O332
14.00–14.15
Opportunistic infections in immunocompromised but
virologically suppressed HIV-1 infected patients
Wendy Bannister (UK)
O333
14.15–14.30
Treatment discontinuation and virological failure
amongst HIV-positive individuals starting second-line
combination antiretroviral therapy (cART)
Colette Smith (UK)
14.30–15.00
Panel discussion
CS2
15.00–16.30
Update on the Clinical Management of Complex
HIV/AIDS Cases: Interactive Session held in
collaboration with IAS-USA
CS2CH
Chairs: Roy Gulick (USA)
Ian Williams (UK)
Panel: Judith Currier (USA)
Cristina Mussini (Italy)
Cases
CS2.1
•
Strategies for antiretroviral therapy
Roy Gulick (USA)
CS2.2
•
Co-morbidities and complications that impact
antiretroviral decisions
Ian Williams (UK)
CS2.3
•
Current issues in viral hepatitis co-infection with
HIV
Jürgen Rockstroh (Germany)
16.30–17.00
COFFEE
SS6
17.00–18.30
Satellite Symposium: Gilead Sciences Europe Ltd
Understanding and overcoming the challenges of late
presentation of HIV patients
SS6CH
Chair: Jürgen Rockstroh (Germany)
SS6CH
17.00–17.10
Welcome
Jürgen Rockstroh (Germany)
SS6.1
17.10–17.30
The epidemiology of late presentation in HIV
Caroline Sabin (UK)
SS6.2
17.30–17.45
Strategies to encourage earlier presentation and
diagnosis: The European experience
Antonio Antela (Spain)
SS6.3
17.45–18.00
Strategies to encourage earlier presentation and
diagnosis: The US experience
Yvette Calderon (USA)
SCIENTIFIC PROGRAMME (continued)
SS6CH
18.20-18.30
Summary and close
Jürgen Rockstroh (Germany)
18.30–20.00
POSTER RECEPTION
THURSDAY 13 NOVEMBER
O41
08.30–10.00
Hot Topics and Late Breakers 1
O41CH
Chairs: Eric Sandström (Switzerland)
Schlomo Staszewski (Germany)
O411
08.30–08.50
HIV–TB co-infection and TB drug resistance: an
emerging threat to HIV and TB programmes
Gerald Friedland (USA)
O412
08.50–09.05
Factors associated with poor clinical outcome among
HIV-infected patients with TB in Europe and
Argentina. The HIV/TB collaborative study
Daria Podlekareva (Denmark)
O413
09.05–09.20
Pharmacokinetics of once-daily etravirine without
and with once-daily darunavir/ritonavir in
antiretroviral-naïve HIV-1 infected adults
Thomas Kakuda (USA)
O414
09.20–09.35
48-week data from Study AVX-201: a randomised
phase IIb study of apricitabine in
treatment-experienced patients with M184V and NRTI
resistance
Susan Cox (Australia)
O415
09.35–09.50
Efficacy and safety of 48-week maintenance with QD
ATV vs. ATV/r (both + 2NRTIs) in patients with VL
<50 c/mL after induction with ATV/r + 2NRTIs:
Study AI424136
Santiago Moreno (Spain)
09.50–10.00
Panel discussion
10.00–10.30
COFFEE
O42
10.30–12.05
Hot Topics and Late Breakers 2
O42CH
Chairs: José Gatell (Spain)
Ian Weller (UK)
O421
10.30–10.50
When to start therapy? The patient’s viewpoint
Gus Cairns (UK)
O422
10.50–11.05
Do the disadvantages of late initiation of HAART
persist in patients achieving and maintaining viral load
suppression for a year on HAART?
Laura Waters (UK)
O423
11.05–11.20
Risk of new AIDS-defining events in patients with
advanced immunodeficiency during suppressive
HAART: results from the German ClinSurv cohort
Alexander Zoufaly (Germany)
O424
11.20–11.35
Resistance development in virological failures with
DRV/r or LPV/r: 96-week analysis of the Phase III
TITAN trial in treatment-experienced patients
O425
11.35–11.50
Efficacy and safety of maraviroc in
treatment-experienced patients infected with R5 HIV-1:
96-week combined analysis of MOTIVATE 1 and
2 studies
David Hardy (USA)
11.50–12.05
Panel discussion
12.05–12.15
Closing Remarks
12.05–12.10
Closing comments from the EATG representative
Wim Vandevelde (Portugal)
12.10–12.15
Closing comments from the Congress Chairperson
Ian Weller (UK)
12.15–13.00
LUNCH AND CLOSE OF CONGRESS
KEYNOTE LECTURERS
We are delighted to have secured contributions from the following internationally renowned
individuals and hope that the information below will be of interest in relation to the Keynote
Lecture session on Sunday evening following the Official Opening.
Christine Katlama has worked in the field of HIV since 1982 and was
involved in the discovery of HIV-2 in 1986. Her group first demonstrated
the impact of HAART on immune reconstitution and works extensively in
the field of new drugs and resistance.
Professor Katlama is a founder member of ORVACS, which is developing
a therapeutic vaccination programme for HIV-infected patients. As a
founder and President of Solthis (Solidarité Thérapeutique & Initiatives
Contre Le SIDA), a non-governmental organisation, she is also heavily
involved in access to HIV treatment and education in developing
countries.
Professor Katlama was President of the European AIDS Clinical Society until July 2004, and remains
an active member, involved in many educational initiatives. She is a member of the editorial boards
of several journals, including
HIV Medicine
and
AIDS
.
AUTHOR INDEX
Aarons, L P241 Abad, F P162 Abdalla Elteer, A P214 Abdel-Kader, L P141 Abdon, A P78 Abrescia, N P3 Absalon, J P8, P136* Abu Bakar, M P305* Acinapura, R P166 Ackad, N P81 Adesola, O P172 Adeyemi, A P172* Adorni, F P34 Adorni, FA P194 Aggett, S P229* Agostinone, A P152 Agud Aparicio, J P93, P100,
P173 Aguirrebengoa, K P33 Ahmed, N P227 Ahmed, S P79 Aich, B P193 Airoldi, M O213, P167 Álamo del Rodríguez, M P93 Alas, B P68 Albalate, M P128 Alcalde-Encinas, M P164, P254 Alcarez, C P33 Alcorn, K O421 Alessandra M. Martino, A P214 Ali S. Bengleil, A P214 Allavena, C P26* Allegri, G P313 Almasi, F P46*, P287* Almeida, I P51 Almeida, J P288 Aloisi, M P177 Alonso, P P288 Altclas, J O414 Alterio, L P152 Altice, F P240 Álvarez, Á P89 Álvarez, M P54, P78 Ambar, R P196, P209 A-Megido, J P290 Amiramini, S P212 Ammari IME P214 Ammassari, A P3, P166 Amoroso, A P121 An der Heiden, M O423 Ancock, B P116* Andersen, T P90 Anderson, J O422, P73*, P203 Andrade, M P89 Andreoni, M P3, P56 Andrews, L P240 Angeletti, G P118 Anghel, N P257 Antela, A SS6.2, P44
Antinori, A P3*, P166, P169, P179, P292 Antinori, S P274 Antoniadou, A P186, P294 Antonopoulou, S P105 Apostolova, N P120, P161* Aquilina, C P29 Arama, V P255 Arastéh, K P24 Arazo, P P64 Arbune, M P261* Arechavala, A P252 Arildsen, H P90 Arranz, J P53 Arredondo, M P20 Arribas, J P44, P64, P308 Arumainayagam, J P15 Asghar, A P248* Ashby, J P260 Aster, V P295* Avidor, B P188 Avihingsanon, A P244* Awni, W P95, P101, P245, P247 Awunor, C P149 Ayala, E P288 Ayoub, A P154* Azijn, H P181, P189
Babu, C P79 Back, D O121, O12CH, P6,
P233, P237, P238, P250 Badal-Faesen, S P198 Bai, F P1, P88, P97, P167 Baietto, L P233 Bailey, A P260, P262* Bailey, M P297 Baily, G P203 Bakoyiannis, G P124 Balcarek, K P147 Baldelli, F P10, P84, P118 Balestra, P P292 Balle, N P174 Ballesteros, D P120, P161 Ballestri, S P139, P140 Balogh, A O415 Bambumba, A P79 Bandivdekar, A P211 Bánhegyi, D P22 Bannister, W O332* Barassi, A P235 Barda, B P202 Barker, R P262 Barlow, P P289 Barranger, E P222 Barreiro, P P128, P137, P138,
P265, P268, P284, P286 Barrieshee, A P278* Barrios, A P173, P251
Barros, C P173 Barrufet, P P92 Basilico, C P234 Bassaris, H P124 Bastos, R P288 Battegay, M CS1CH Batuca, J P96 Baumgardt, C P32 Baumgarten, A P7, P75 Baxter, J P190, P192* Beauvoit, B P147, P148 Becker, E P304* Beckerman, K O221* Bedimo, R P9* Beets, G P23, P27 Beghetto, B P115, P156, P300 Behrens, G SS4.2 Beijnen, J P242 Belaebi, L P46 Belda, A P162 Bele, V P193 Belfiori, B P84 Bellagamba, R P292 Bellido, R P142 Bellistrì, G P1, P88, P97 Bellos, N P21 Benea, O P255, P261 Benetucci, J P252 Bengleil, AS P214 Beniowski, M O331 Berenguer, J P54 Berg, J P315 Berg, T P201 Berger, F P135, P160 Bergin, C P132, P155, P276,
P293 Bergman, J P222 Bernardi, S P213 Bernasconi De Luca, D P234 Bernstein, B P95, P101, P110,
P245, P247 Berry, A P249 Bertheau, P P269 Bhatti, L P190, P192 Biagetti, C P123 Bickel, M P18*, P32, P59*,
P122 Bigoloni, A P45 Bijuklic, K P200 Billing, N P98* Bini, T O213, P88, P153, P167,
P235 Bino, S P87 Biondi, M P235 Bisi, L P167, P273 Bisicchia, F P17 Bisimba, J P175* Bissé, E P210 Bissio, E P317*
Name Activity Name Activity Name Activity
Blanc, C P38 Blanco, F P20*, P42, P66, P128, P137* Blanco, JL P64 Blanco JR P64 Blas-García, A P120*, P161 Blaxhult, A P82 Bobrik, A O134* Bodtlaender, A P59 Boffito, M P241 Bogner, J O212 Bolan, R P303 Bonfanti, P P19, P74 Bonjoch, A P50*, P150* Bonnet, J P147, P148 Bonora, S P233 Boorman, H P28 Boothby, M P113* Borderi, M P123* Borghi, V P273* Borras-Blasco, J P162* Boschi, A P30 Bossola, M P177 Bottecchia, M P284 Bottieau, E P270, P283* Bouzas, M P252 Bovee, I P208 Boven, K P2*, P239 Bower, M P14, P49, P116, P248 Boyce, C P121 Boyd, K O122 Boyd, M P70 Boyle, N P199 Bracciale, L P168 Bradbeer, C P305 Branco, T P96, P155 Brandolini, M P56 Braun, P P12, P43, P201 Bravenboer, B P55 Bravo, I P65 Bray, D P206 Breiden, J P246 Brennan, M P199, P246 Brenner, B O114 Brodt, H P32 Brogan, A P306, P309 Brosa, M P314 Bruce, R P240* Brun, F P92 Bruyand, M O314, O412 Buelens, A P239 Burapat, C P259 Burger, D P244 Burgos, A P80, P117, P264*,
P308 Burk, M P188 Butler, K O122 Buvé, A P223
Buxton, G P107* Buzon, M P50 Byakwaga, H P70*
Caballero, E P40 Cabie, A P26 Cabrero, E P80, P117, P264, P308 Caffagni, G P140 Cahn, P O414 , O13CH Cain, K P259 Cairns, G O421* Cairns, V P41 Caixas, U P96 Calbi, M P99 Calcagno, A P233 Caldas, C P296* Calderon, Y SS6.3 Callegaro, A O213 Caluwaerts, S P223 Calvez, V P29, P178* Calza, L P165 Camacho, R P51 Camanni, G P10, P118* Cambrea, S P226* Campbell, L P260* Candido, V P196 Canestri, A P38* Cañizal, A P252 Cano-Sánchez, A P164, P254 Capasso, M P39 Capetti, A P31* Caramma, I P274 Carcaba, V P290 Cardellach, F P142, P143, P144, P146 Cardoso, S P296 Carganico, A P13, P25 Carini, E P45 Carlebach, A P18 Carocci, C P69* Carosi, G O415, P52, P267,
P282 Carradori, S P74 Carrilho, C P288 Casado, J P80* Casana, M P88, P97, P153*,
P235* Casas, E P65, P173 Caseiro, M P196, P209 Casillas Rodriguez, J P104, P108 Cassetti, I O414, P4 Castagna, A P36, P37, P45, P202 Castaño, M P141 Castera, M P162 Castilla, V P251 Castro, A P42, P92
Castro Lopez, H P104*, P108* Cattelan, A P56 Cauda, R P99, P243 Caum, C P150 Caumes, E P269 Cavassini, M P231 Caylá, J O412 Ceccherini-Silberstein, C P35,
P179 Cecchini, D P252* Celesia, B P17* Cervero, M P173* Cervero Jiménez, M P93*,
P100* Cesari, M P1, P274 Chadwick, D P107 Chaikan, A P237* Chandramani, S P15 Chanmano, S P244 Charles, M P229 Charlotte, F P269 Chaudhary, M P310 Chauret, N P298 Chein, M P303 Cheng, A P4 Chernai, N P222 Chew, N O323*, P109* Chiavaroli, R P106, P131 Chierakul, N P237 Chiesa, E P206 Chiesi, A O331 Chilton, D O112* Chini, M P47, P105 Chiodo, F P123 Chiotan, C P255 Chirianni, A P3 Chiu, Y P95 Chranioti, K P294 Christensen, J P90 Christie, A P315 Chuah, J P72 Chuchuttaworn, C P237 Chui, Y P245, P247 Cicconi, P P153, P235 Cingolani, A P168 Ciraru-Vigneron, N P222* Citton, R P213 Clark, D P203* Clay, E P303 Clerici, M P206 Clermont, P P298 Clifford, D O211* Clotet, B O331, P23, P33, P42,
P50, P54, P58, P64, P65, P67, P114, P142, P150, P157, P171, P176, P191, P272* Clumeck, N P23*, P48, P289 Coakley, E P190, P197 Cobos-Trigueros, N P164, P254
AUTHOR INDEX (continued)
Coelho, R P296 Coen, M P206 Cohen, C O214*, SS2.2, SS5.2,
P157 Cohen, D P110, P170 Cohen, K O124 Colafigli, M P243 Colberg, K P62 Colby, D P77 Colebunders, R P228, P270 Cologni, G P52, P282 Colson, A O214 Comi, L P88, P97, P153, P235 Compagnucci, A O222 Compangocci, A P46 Comparini, R P209 Conner, C P121, P240 Contés, E P251 Conway, B P81*, P277*, P278 Cooper, C P28 Cooper, D O414, O31CH, P70,
P244, P297 Cordes, C P2 Córdoba, M P20 Coria Ramirez, E P108 Corpolongo, A P3 Corsi, C P69 Corso, N P133 Cortés, C P92 Cosín, J P53, P78, P134 Cossarini, F P202 Costagliola, D P299 Costarelli, S P52 Cotter, E O323 Coulter-Smith, S P199, P246 Couto-Parada, X P203 Covington, D O221 Cox, S O414* Cozzi-Lepri, A P183 Crauwels, H P239* Crespo, M P40 Cristina, M P88 Cui, Y P247 Cuko, G P153 Cupsa, A P257 Curran, A P40, P54 Currier, J PCH Curtin, J P57 Cusato, M P234 Cuthbertson, Z P6, P250 Cuzin, L P26
Da Cunha, C P22 Da Silva, B P95, P101*, P110*,
P245 Daikos, G P186 D’Alessandro, M P19 D’Amico, R P125, P139, P140
Daniels, R P14* d’Aquin Toni, T O114 Darbyshire, J O12CH d’Arminio Monforte, A O314,
O332, O23CH, P1, P88, P97, P153, P235 D’Arrigo, R P35, P179 Das, A P28 Das, S P15*, P113 Däumer, M P201 Davies, A P91 Davies, G P237 Davis, C P121* D’Avolio, A P233 de Barra, E P132, P293 de Béthune, M O424, P189 De Boer, M P283 de Gaetano Donati, K P99* De Gennaro, M P206 de Guzmán, M P251 de la Calle, O P314 De la Torre, J P65, P112 de Lazzari, E P53 De Longis, P P169 De Luca, A P99, P168, P243 De Meyer, S O424*, P21, P24,
P181, P189 De Pablo-Bernal, C P89 De Paepe, E O424 De Silvestri, A P30 De Smedt, G P23, P27, P189,
P272 De Socio, G P19, P74 De Terlizzi, F P215 De Wit, S O314, P36, P37, P48*, P289 De Wolf, H P205 Deeks, S O311* Degen, O P62* Deig, E P78, P146 DeJesus, E O214, O413, P61,
P63 del Álamo Rodríguez, M P100 del Arco, A P102 Delforge, M P48, P289 Delfraissy, J O415 Delgado, C P51 Delgado-Alves, J P96 Della Torre, L P202 Dellamonica, P P26 Deloof, A P205* Delpech, V O112 Demeester, R P283 Demopoulos, C P105 Deshpande, A P211 Deveaud, C P147, P148 DeWet, J P81 Di Biagio, A P215 Di Castelnuovo, A P99
Di Giambenedetto, S P168, P243 Di Masi, F P152 Di Matteo, L P152 Di Perri, G ES2.2, P233 Di Vincenzo, P P39, P194 Diaz, M P40 Diaz, R P209 Dickinson, L P237, P241* Diderichsen, P P245 Dierynck, I O424, P189 Dietz, B P307, P311, P312 Diniz, A P51 Doan, T P95, P101 Dobosz, S P216*, P217 Doerholt, K O122 Dolara, A O213 Domingo, P ES1.3, P42, P53,
P67, P134, P191 Dominguez, K O221 Doran, P O323 Dragsted, U P6, P250 Dravid, A P193 Drechsler, H P9 Duarte, N P196 Dufty, N P249 Duiculescu, D P224, P275* Dumitrescu, F P257* Duncan, A P204 Duncan, F P277 Dunlop, W P310* Duvivier, C P26
Eberhard, A P195 Eberle, J P200 Eberle, S P86 Ebrahimi, R P61, P63 Eccleston, K P79* Echeverría, P P53, P65*, P67*,
P150 Edwards, C P91 Edwards, I O121 Egle, A P200 Egnell, K P256 Ehret, R P43 ELA Group*, P65 Elbasha, E P310 Elion, R O214 Ellis, E P219, P225 El-Sadr, W O314 Else, L P6, P199, P241, P246,
P250* Elteer A P214 Emery, S P70, P297 Emmelkamp, J P266, P304 Ene, L P275 Enejosa, J P4 Eng, S P198* England, K P218*
Name Activity Name Activity Name Activity
English, S P103* Epting, T P210 Eron, J P27 Esplugues, J P89*, P120, P161 Esposito, R P34, P125, P273,
P300 Esser, S P41*, P76* Estany, C P150 Estrada, V P54 Etzel, A P4 Everhard, F P306, P309 Evers, S P163
Fabbiani, M P243* Fakoya, A PCH Falco, V P40 Fang, W P240 Fantoni, M P99 Farajallah, A P8, P61, P63 Fardel, V P231 Farrell, G P276 Fätkenheuer, G O425, P12,
P157*, P195, P266 Fernandez, S P112 Ferramosca, S P39 Ferreira, A P296 Ferreira, D P296 Ferrer, E P44, P53, P92 Ferrer, M P114, P171, P176 Ferrer, P P54, P78 FHDH-ANRS 04, the P299 Filice, C P119 Firlag-Burkacka, E P184 Fisher, M O332, O422 Fituri, OA P214 Flaherty, J P61, P63 Flamm, J P157 Flandre, P P26 Fleming, C P199 Florence, E P36*, P37, P228*,
P270*, P283 Flores, J P64 Floyd, S P11 Foggia, M P3 Fomundam, H P73 Fontas, E O314 Forbici, F P179 Force, L P92 Fortuny, C P143, P144 Fox, R O31CH, P103, P219,
P225, P253*, P291 Fox, S P68 Fox, Z P183 Francisci, D P10, P84*, P118 Francque, S P270, P283 Fraser, C P277 Fredrick, L P110 Freedberg, K O113 Friedland, G O411*, P240
Friend-du Preez, N P73 Friis-Møller, N O313, O314 Fumaz, C P114, P171*, P176* Furrer, H O412 Fusetti, G P45
Gagliani, L P196, P209 Gaikwad, S P193 Galani, L P294 Galindo, M P134 Gallagher, L P277 Gallego, M P102 Galli, L P45, P202 Galli, M P1, P39, P119, P194,
P274 Gallo, C P290 Gallo, L P12, P76 Garb, J O214 Garcia, M P33, P58 García, P P146 García Benaya, E P93, P100 García Lacalle, C P93, P100 Garcia-Alcalde, M P134 García-Bujalance, L P314 García-García, J P164, P254 García-Henarejos, J P42, P44, P164, P254 García-Samaniego, J P268,
P284 Gargalianos, P P124, P186 Garrabou, G P142*, P143,
P144, P146* Garraffo, R P26 Garren, K P312 Garrido, C P20 Garrido, M P134 Garvey, L P301* Gascon, J P288 Gaspar, G P173, P251* Gatell, J O332, O42CH, SS4CH,
P53* Gathercole, L P113 Gatti, F P52*, P267, P282 Gazzard, B SS2CH, SS2.1, PCH,
P14, P16, P49, P116, P129, P151, P248 Geijo, P P42, P92, P134 Genoway, K P277 Georgoulakis, J P294 Geretti, AM SS4.3 Germano, I P96 Gersbacher, E P195 Gervasoni, C P119 G-Franco, A P290 Ghaji, N P149 Ghanem, M P15 Giamarellou, H P124, P294 Giancola, M P166, P169 Gianelli, E P74
Giannaris, M P124 Gianotti, N P3, P45 Giaquinto, C O222 Gibb, D O122, O125, O222* Gibbons, S O121, P199, P233,
P246 Gibbs, S P110 Gibellini, D P123 Giffo, B P29 Gilks, C O125 Gilliam, B P121 Ginocchio, F P215 Giola, M P234* Girardi, E O412 Gisolf, E P55, P60 Giubelan, L P257 Giulianelli, M P169 Giuntini, R P74 Gizinska, J P258 Goelz, J P195 Gogos, H P124 Goikoetxea, J P33 Goldbach, J P41 Golegã, A P209 Gölz, J P76 Gómez-Sirvent, J P221 Gómez-Sucerquia, L P161 Gonzalez, A P130, P302 González, M P221 González, Y P161 Gonzalez-García, J P264 González-Lahoz, J P20, P128,
P137 Gonzalez-Mena, A P64 González-Mestre, V P114 González-Pardo, G P66 Goodrich, J O425, P154 Gorèíková, J P212 Gori, A P97, P167 Gori, C P35 Gorowara, M P244 Graf, B P16* Grana, M P102, P112 Grancea, C P182 Granholm, H P82 Granier, C P83 Grant, D P110 Grebely, J P277 Green, H O112, O222 Gregis, G O213 Greil, R P200 Griffa, L P80, P117*, P264 Grima, P P106, P131 Grima, PF P106*, P131* Grimm, K P63 Grinsztejn, B P21, P24 Grisaru, G P188 Groeneveld, P P55 Grossi, P P234
AUTHOR INDEX (continued)
Grosskurth, H P11 Grosso, C P74 Grulich, A O321* Guaraldi, G P34*, P94*, P115,
P125*, P139*, P140*, P156, P177, P300* Guatelli, K P196 Guelar, A P130, P302* Guevara, F P20 Guiget, M P269 Gulick, R O425, CS2.1, CS2CH Gulizia, R P119* Gupta, A P16 Gupta, N P158 Gupte, N P193 Gussio, M P17 Gute, P P18, P32 Gutierrez, F P53 Gutierrez, M P67 Gyllensten, K P82*
Haas, B P83 Habel, A O214 Haberl, A P32, P71*, P76 Haigney, Z O413 Hain, J P86* Haine, D P81 Hairrell, J P110 Hakim, J O132* Hamlyn, E P260 Hamouda, O O423 Han, D P197 Hanhoff, N P71 Hankins, C CoS.1 Hanna, G P185 Hanzlíková, J P212 Hardy, WD O425* Harris, M P271 Harrison, L O112 Hartkoorn, R P238 Hartmans, N P208 Harxhi, A P87* Hassoun, G P188 Hatz, C CS1.5 Hatzakis, A P47, P186 Haubrich, R P27*, P312 Hay, P P6, P250 Heera, J O425 Hegener, P P135, P160 Hemmett, L P313 Henke, J P135, P160 Hennessy, M P91, P236 Hepburn, M P219, P225 Hernandez-Quero, J P42, P64 Herrero-Segastume, V P164,
P254 Hertling, S P62 Hervás, R P173 Hervey, C P207
Hill, A P5*, P36, P37, P127, P178, P181 Hirschel, B CoS.2, ES2.1 HIV/TB Study Group O412 Hjelmgren, J P313 Hodder, S P63* Hoepelman, A P60 Hoepelman, I P55 Hoetelmans, R P239 Höhn, C P43 Høj, L O313, P183 Hojman, M P227* Holas, C P95 Holm, S P71 Holmes, P P14, P248 Holodniy, M P9 Horban, A PCH, P184 Hornberger, J P318 Hosein, S CoSCH Hosseina, M P277 Hristea, A P255 Huang, W P197 Hughes, P P11 Huitema, A P242 Hull, M P271* Husstedt, I P163* Hutt, E P306*, P309*
Iacoviello, L P99 Iannotti, N P99 Ibrahim, F P262 Idris El Ammari, I P214 Ilie, M P226 Imaz, A P40* Ionescu, C P275 Iosipenco, M P255 Iribarren, J P33, P221, P314 Isaacs, R P207 Isenman, H P248 Ive, P O124, P2 Iwuala, S P126* Izopet, J P26
Jackson, A P276 Jackson, AGA P129, P151 Jackson, F P83 Jackson, V P199*, P246 Jadhav, S P211* Jaegel-Guedes, E P195 Jaeger, H P7, P13, P25, P41,
P75, P195 Jaffe, H O224* Jan, E P91 Janke, M P266 Jansen, K P272 Jarrin, I P279 Jauer, M P200 Jayasuriya, A P249
Jensen, J O214 Jimenez, I P268 Jiménez-Nácher, I P66 Johnson, M O333, O21CH, P6,
P23, P83, P250 Judd, A O122 Jullien, V P287 Jusdado, J P251 Jusdado Ruiz-Capillas, J P93,
P100
Kabeya, K P48 Kachman, E P188 Kaiser, R P201 Kakuda, T O413*, P272 Kalath, T P257 Kambraki, M P214 Kanjavanit, S O222 Karafoulidou, A P47, P186 Karaiskos, I P294 Karakitsos, P P294 Kasteren, M P55 Katabira, E O131* Katlama, C KL2*, SS2.3, ES2.4,
P21*, P22*, P26, P38, P269, P272 Katsarolis, I P294 Kavatha, D P294 Kawiya, J O125 Kedem, E P188 Kelleher, A P297 Kelly, S P132* Kerndt, P P303 Kerr, S P244 Kestens, D P239 Khanna, M P158 Khatib, N P49 Khaykin, P P32, P122 Khoo, S O121*, O123*, O125,
PCH, P6, P199, P233, P237, P238, P241, P246, P250 Kiely, B P293 Kieran, J P246, P276* Kigen, G O121 Kim, D P247 Kimaiyo, S O121 Kinder, F O214 Kint, I P223*, P228 Kirk, O O212, O313, O332,
O412 Kirschner, J P147, P148 Kiss, L P197 Kitas, G SS3.3 Kittikraisak, W P259 Kityo, C O125* Kjær, J P183* Klauke, S P12, P18, P32, P59 Klein, C P95*, P101, P245, P247
Name Activity Name Activity Name Activity
Knecht, G P13, P25, P59, P122 Knechten, H P12, P13*, P25,
P43*, P195 Knight, E P277 Knobel, H P53, P130, P302 Koegl, C P75* Koeppe, S P25 Kok, P P263 Kollan, C O423 Komninakis, S P196, P209 Konig, J P295 Konopnicki, D P289* Kontos, A P85 Koole, O P228 Koopmans, P P55 Körber, A P76 Kordossis, T P85*, P186 Kourkoudi, S P124 Kovacs, C P81 Kowalska, J O313* Kraemer, S P29 Kraja, D P87 Kreuzberg, C O423 Krivine, A P46 Ktorza, N P38 Kumar, R P72, P310 Kumarasamy, N P72, P111 Kumari, B P15 Kuritzkes, D O115* Kurowski, M P59 Kwan, W P238
La Rosa, R P17 Labarga, P P128*, P137, P265,
P268 Lacombe, K O212 Lafuente-Lafuente, C P279 Laird, J P291 Lalezari, J O413 Lallemant, M O222 Lambert, J P109, P199, P246* Lampe, F O333 Lampreia, F P96 Lane, HC KL2* Larrouse, M P54 Larson, J P197 Lascoux-Combe, C P299 Lataillade, M P180*, P185 Latarska-Smuga, D P258 Laterreur, J P298 Lathouwers, E O424 Lattanzi, A P94 Lattimore, S O112 Lauriola, M P206 Laursen, T P174 Law, M O314 Lazanas, MC P47, P105, P186 Lazanas, ML P124
Lázaro, P P308 Lazzarin, A O415, P21, P45,
P76, P202, P272 Lazzaroni, L P234 Lebrecht, D P145, P147, P148 Ledergerber, B O212, O331 Lee, A P203 Lee, V P79 Leen, C P315 Lefebvre, E P157 Lefevre, V P222 Legrand, J P55 Lekander, I P315* Leleu, G O415 Lennemann, T P122 Leoncini, L P69 Letang, E CS1.3, P288* Levy, Y SS1.3 Leyes, M P221 Li, J P101 Libertone, R P292 Lim, P P72 Limb, S P203 Lin, S P240 Lin, Y P101 Lins-Filho, A P209 Lisv
ka, M P212 Liuzzi, G P292* Llibre, J P42*, P50, P58, P191 Lo Caputo, S P35*, P206 Lo Cicero, M P39 Lobo, J P290* Loeschel, E P83 Logue, K P81 Lonardo, A P139, P140 Longo, N P81 Lopardo, G P317 López, R P65 López-Aldeguer, J P134, P221 Lopez-Bernaldo de Quiros, J
P64 López-Blánquez, R P142 López Gomez, M P44 Lorenzini, P P3, P169, P179 Loria, P P139, P140 Losina, E O113 Losso, M O414 Loutfy, M P318 Loy, A CS1.1 Loyo, K P124 Lozano, F P134 Luechters, G P266 Luminos, M P255 Lundgren, J O212, O312*,
O313, O314, O331, O332, O412, P183 Lutwana, F O125 Lutz, T P12, P13, P25, P59, P122
Lyall, H O122, O223*, O222, O22CH Lynen, L P283 Lyons, F P293
Maa, J P8, P61, P63 MacConnachie, A P103, P219,
P225, P253, P291 Machala, L O331, P295 Macias, J P141* Mackie, K P204 Mackintosh, C P253 MacPherson, P CoS.3 MacRae, K P297 Mactier, H P219, P225 Madeddu, G P19, P74 Madejon, A P284 Madruga, J P4* Maes, P P223 Magafas, N P124 Magenta, A P153 Maggiolo, F O213*, P3, P167* Magiorkinis, E P47, P186 Magiorkinis, G P47, P186 Magnier, J P279 Mahungu, T P238 Mahungu, TW P6*, P250 Maida, I P138*, P286 Mair, R P229 Majluf Cruz, A P104, P108 Makne, A P193 Malashenkov, E O412 Maldonado, M P227 Malincarne, L P10* Mallal, S PCH Mallolas, J P53 Mallon, P O322*, SS6.4 Mallon, PW P70 Maltez, F P51 Manata, M P51 Mancini, M P136, P180 Manconi, P P133 Mandalia, S P129, P151 Manfredi, R P165* Mangafas, N P105 Manigart, Y P289 Manolescu, L P182* Manonelles, G P227 Mansinho, K P51 Manzini, L P273 Manzoli, L P19 Marasca, G P168 Marcas, C P226 Marcelin, A P178 Marchetti, G P1, P88*, P97 Marconi, P P74, P166, P179 Marcotullio, S PCH Marczyñska, M O222, P216, P217*
